143 results about "Fetus" patented technology

Compositions, methods, kits, systems, and software are provided for non-invasive prenatal testing for autosomal recessive diseases. Next generation sequencing is used to sequence maternal and fetal DNA isolated from maternal plasma by probe capture. The fetal fraction of the sequencing reads for DNA isolated from maternal plasma is estimated by counting single nucleotide polymorphisms (SNPs) for which an allele is detected that is present in the paternal haplotype but absent in the maternal haplotype, based on the assumption that SNPs having a paternal allele belong to the fetal DNA. The fetal fraction is bioinformatically enriched by excluding sequencing reads over a specified length via in-silico size selection, which increases fetal genotype prediction accuracy. Parental haplotype information together with the read ratios observed at the linked SNPs is used to predict the fetal genotype at a site of a mutation linked to the autosomal recessive disease.

The invention discloses a quality grade and risk identification acquisition method for a prenatal ultrasound key anatomical structure. The method comprises the following steps: firstly, automatically identifying a standard section of a fetus and carrying out pixel-level segmentation on the key anatomical structure; on the basis, indexes such as visibility, orientation consistency and boundary integrity are extracted, a comprehensive quality score is calculated, and corresponding quality grades and risk identifiers are output according to threshold rules, so that an objective, consistent and traceable quality evaluation closed loop is formed, segmentation results are structured into quantitative indexes and graded alarms, and the quality evaluation accuracy is improved. The system can realize automatic evaluation and risk prompt of the standard section quality on the premise of not changing the existing clinical process, and improves the quality control efficiency and consistency.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

The invention provides methods for assessment of fetal DNA samples using target-enriched multiplexed parallel analysis. The methods of the invention utilize TArget Capture Sequences (TACS) to thereby enrich for target sequences of interest, followed by massive parallel sequencing and statistical analysis of the enriched population. The methods can be used with fetal or embryonic DNA samples, for example for detection of the presence of genetic abnormalities, e.g., for purposes of IVF Pre-implantation Genetic Screening (PGS) and Diagnosis (PGD). Kits for carrying out the methods of the invention are also provided.

The invention relates to the field of image processing, in particular to a fetal hydrocephalus three-dimensional reconstruction and operation planning method based on multiple modalities, which comprises the following steps: obtaining key points and ventricular postures in a three-dimensional point cloud during each three-dimensional reconstruction, predicting the ventricular postures during the next three-dimensional reconstruction, and obtaining prediction residual errors; historical three-dimensional reconstruction key points are clustered based on prediction residual errors to obtain all categories, and when three-dimensional reconstruction is carried out again, the obtained three-dimensional point clouds are further deleted and added based on the categories. According to the invention, errors in a matching fusion process and errors in a prediction process during three-dimensional reconstruction are avoided, and the accuracy of a three-dimensional reconstruction result is improved.

The application relates to the technical field of data management control, and particularly discloses a data management control method and system based on a maternal and infant one-stop learning cloud platform, which comprises the following steps: based on real-time collected maternal and infant physiological data, maternal and infant historical health records and user learning behavior data, a multi-modal maternal and infant user portrait containing dynamic health state labels and dynamic learning ability labels is constructed; based on multi-modal maternal and infant user portraits of all maternal and infant users, multi-dimensional health horizontal comparison factors of pregnant women and fetuses or infants in each maternal and infant user under each division attribute and each division level are determined, and maternal and infant health deviations of each maternal and infant user are analyzed; based on the multi-dimensional health horizontal comparison factors of the pregnant women and the fetuses or the infants in each maternal and infant user under each division attribute and each division level and the maternal and infant health deviations, intelligent adaptation of multiple services is driven; and a closed loop from health deviation to education content, health plan and deviation improvement is formed.

Disclosed herein is deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure. Use of deuterated buprenorphine prevents or reduces exposure of the fetus to opioids used by the mother. Use of deuterated buprenorphine may prevent or reduces exposure of the fetus to harmful metabolites of buprenorphine.

A wearable birthing simulator and method of operating thereof are disclosed. The simulator includes a housing that is securable to a subject and the housing defines an opening. Positioned within the housing is a uterus simulator and a removable fetal model contained therein. Coupled to the uterus simulator is a birth canal simulator. A birthing device comprises an actuator assembly in communication with the controller for automatically moving the fetal model towards the birth canal simulator. One or more sensors are mounted to the housing and are electrically connected to the controller for detecting movement of the fetal model by the birthing device. The feedback device is configured to provide the haptic feedback to the subject in response the movement of the fetal model toward the birth canal simulator. The disclosed simulator may be used to simulate a variety of childbirth scenarios.

The present application relates to devices for monitoring pregnancy or labor. In one embodiment, the device includes an electromyography (EMG) sensor having two or more EMG electrodes that monitor fetal or maternal activity during pregnancy or labor, and one or more position sensors that monitor the relative positioning of the two or more EMG electrodes during fetal or maternal activity. In one embodiment, the device includes a monitoring apparatus that is placed on a body and has a plurality of sensors integrated into the monitoring apparatus, the plurality of sensors including at least a first sensor configured to detect a first type of signal from the body indicative of a first type of fetal or maternal activity during pregnancy or labor, and a second sensor configured to detect a second type of signal from the body different from the first type of signal also indicative of the first type of fetal or maternal activity during pregnancy or labor.

Examples described herein provide a computer-implemented method that includes receiving a non-invasive transabdominal fetal electroencephalogram (TA-fEEG) signal associated with a pregnant subject. The method further includes using the first machine learning model to reduce unwanted noise in the TA-fEEG signal. The method further includes reconstructing a fetal electroencephalogram (fEEG) signal from the TA-fEEG signal using a second machine learning model.

The invention provides a TRPM8 protein mutant and application thereof, relative to an amino acid sequence of a wild type TRPM8 protein, the TRPM8 protein mutant comprises mutation at one or more positions selected from the 825th site, the 864th site, the 891th site, the 897th site, the 915th site, the 917th site, the 925th site, the 927th site, the 928th site, the 932th site, the 945th site, the 946th site and the 948th site. The invention also provides a separated nucleic acid which is used for coding the TRPM8 protein mutant. The invention also provides a vector containing the isolated nucleic acid and a genetically recombinant porcine fetal fibroblast. According to the invention, a key site which can effectively reduce the cold activation level of the pig TRPM8 without influencing other activation functions is screened, and a new material is provided for animal breeding improvement.

The present invention pertains to a method for determining DNA sequence variation in a fetus from samples of the fetus and parents using a Bayesian framework. The method comprising the following steps: receiving the samples comprise genomic sequence data covering one or more genomic regions of interest in relation to the fetus and the parents; processing the received samples at least in part based on a reference genome; computing a probability of fetal genotypes based on the samples using the Bayesian framework, where the Bayesian framework computes a posterior probability of whether a DNA sequence variant is present in the samples based on a prior probability and a likelihood function; and determining, based on the posterior probability of fetal genotypes, whether the DNA sequence variant is present in the fetus.

Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and / or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

The present invention relates to a method for determining the sex of a fetus in an ungulate.

The present application relates to the field of paternity determination, and provides a non-invasive prenatal paternity relationship determination method and system and electronic equipment, the method comprising: obtaining a paternal DNA sample and a pregnant woman's plasma free DNA sample, the pregnant woman's plasma free DNA sample including a fetal DNA sample; performing genomic sequencing on the paternal DNA sample and the pregnant woman's plasma free DNA sample; after genotype filling, determining the paternal genotype and the fetal genotype; calculating the kinship coefficient of the paternal genotype and the fetal genotype; based on the kinship coefficient of the paternal genotype and the fetal genotype and a pre-constructed corresponding relationship between the kinship coefficient and the paternity relationship, determining the paternity relationship between the father and the fetus. The present application solves the defects of low detection efficiency and high technical cost in the related art, and is convenient to operate, completely non-invasive, and does not cause any physiological interference to the pregnant woman and the fetus; the detection can be carried out from the seventh week of pregnancy, and is suitable for precise identification of the biological father of the fetus and unrelated individuals.

A composition for treating a patient with a tissue disease or malformity has a composition containing amniotic fluid. The amniotic fluid has a quantity of gender specific amniotic fluid based on a gender of a fetal source. A method of treating a patient with a tissue disease or malformity comprises the steps of: identifying the tissue region to be treated and selecting a location to apply either topically or by injection or inhalation a composition containing amniotic fluid; selecting the composition containing amniotic fluid wherein the amniotic fluid has a quantity of gender specific amniotic fluid based on a gender of a fetal source allowing more specific targeted growth factors to be used for specific disease processes; and applying or injecting the composition at or into the selected location.

The invention discloses a method and device for obtaining a baby simulation image based on a fetus ultrasonic image, and the method comprises the steps: obtaining the ultrasonic image of a fetus, and the ultrasonic image is a 3D or 4D ultrasonic image; calling a facial feature extraction model to extract facial features in the ultrasonic image; obtaining an infant face image based on the face features and the ultrasonic image, wherein the infant face image comprises prediction of the long phase of the fetus after birth; and acquiring a baby simulation image based on the baby face image. According to the method, the infant simulation image after the birth of the fetus can be obtained based on the 3D or 4D ultrasonic image of the fetus, and compared with the 3D or 4D ultrasonic image, the infant simulation image can more truly reflect the length phase of the birth of the fetus, and the requirement of people for observing the length phase of a future infant is met.

The invention relates to the technical field of medical diagnosis, and discloses a fetal nervous system auxiliary diagnosis method based on big data. The method comprises the following steps: collecting nervous system monitoring data of a plurality of fetuses; performing prenatal whole pregnancy dynamic tracking regularization processing on the ultrasonic radio frequency signal sequence, aligning ultrasonic characteristic differences among different fetuses, and generating a fetal nervous system development ultrasonic characteristic dynamic change curve; obtaining a non-pathological feature weight and an optimized association degree quantity of each sampling point, calculating a comprehensive importance score of each sampling point based on a product of the non-pathological feature weight and the optimized association degree quantity, and selecting the sampling points of which the scores are higher than a dynamic threshold value as key feature points; integrating amplitude data and clinical health scores of the regularized feature dynamic change curves of all fetuses at key feature points, and training a diagnosis prediction model by using a gradient boosting decision tree algorithm; and processing the ultrasonic radio frequency signal sequence of the fetus by using the diagnosis prediction model, extracting the amplitude of the key feature points, inputting the amplitude into the model, and outputting a nervous system development outcome risk prediction evaluation value.

In at least one embodiment, a hemoglobin measuring device may include a plurality of sensors, a display configured to present information, and a computing device in communication with the sensors and display and having a processor and a memory storing instructions executable by the processor. The instructions may include instructions to receive, from the sensors, measurements of one or more forms of glycated hemoglobin in a blood samples, determine a total fetal hemoglobin value in the blood sample by performing a peak area summation of all forms of fetal hemoglobin, subtract the total fetal hemoglobin value from 100 to derive a total adult hemoglobin value, determine a glycated fetal hemoglobin value, compare the glycated fetal hemoglobin value to a reference range to obtain a comparison, determine a baseline glucose control value based on the comparison, and output the baseline glucose control value and the comparison to a display for medical evaluation.

Techniques for reducing power consumption by fetal ultrasound transducers are provided. In an example, a fetal sensor device (FSD) comprising a processor, controls operations an ultrasound transducer of the FSD in accordance with a power optimization protocol that results in minimizing power consumption by the FSD, wherein the ultrasound transducer is configured to measure one or more fetal parameters of a fetus using doppler based ultrasound technology, wherein the FSD operates in an active mode that comprises alternating between transmit periods wherein the ultrasound transducer transmits ultrasound signals, and receive periods wherein the ultrasound transducer measures reflected signals of the ultrasound signals that are received by the ultrasound transducer during the receive periods, and wherein the controlling comprises controlling a transmission power of the ultrasound signals and / or a duration of the transmit periods during the active mode in accordance with the power optimization protocol.

The invention proposes a pregnancy risk assessment early warning method and system based on multi-source data fusion, and the method comprises the steps: collecting multi-modal data, carrying out the preprocessing of the multi-modal data, and obtaining first data, and the preprocessing comprises the time sequence alignment, window reconstruction and standardization; extracting physiological features and behavior features from the first data, wherein the physiological features are segmented convolution features of uterine electrical activity on a multi-frequency structure; the behavior feature is a fetus image frame behavior complexity index, is coded by an ultrasonic image sequence and is calculated based on inter-frame similarity; constructing a maternal-fetal interaction state diagram based on the physiological features and the behavior features, and constructing a diagram embedding vector of the maternal-fetal interaction state diagram; the graph embedding vector is obtained by performing propagation type embedding calculation on all node features on a graph, and represents an interactive propagation state of a physiological-behavior signal in a current maternal-fetal system; and performing risk level evaluation on the current pregnancy state based on the maternal-fetal interaction state diagram and the diagram embedding vector, and outputting a risk cause chain.

The invention belongs to the technical field of big data medical health, and particularly relates to a maternal and fetal congenital anomaly case tracking system based on regional big data, which comprises a data acquisition module, a data transmission and storage module, a big data analysis module, a case tracking and early warning module, a patient feedback and intervention module and a case database and cloud management module. The system can monitor the health conditions of pregnant women and fetuses in real time, generate abnormal early warning in time, effectively reduce the missed diagnosis rate and misdiagnosis rate of maternal and fetal congenital abnormalities, and perform intelligent analysis on large-scale maternal and fetal health data through the big data analysis module to find potential disease risks, thereby providing decision support for doctors, and improving the diagnosis efficiency of the maternal and fetal congenital abnormalities. Meanwhile, the system not only can monitor health data of individuals, but also can realize large-scale maternal and fetal congenital abnormality case tracking, promote reasonable configuration and allocation of regional health resources, improve the working efficiency of doctors, reduce errors of manual diagnosis and ensure early intervention of maternal and fetal health.

The present application relates to the technical field of gene detection, in particular to a SNP molecular marker for detecting donor cfDNA of a pregnant organ transplant patient, a detection method and device. The SNP molecular marker for detecting donor cfDNA of a pregnant organ transplant patient is shown in Table 10. The present application uses free DNA in peripheral blood of a pregnant patient and genomic DNA in peripheral blood of a biological father of a fetus as detection objects, adopts liquid phase hybridization capture and high-throughput sequencing technology, uses thousands of SNP sites, obtains the genotype of the fetus through the genotype of the couple, eliminates the influence of cfDNA from the fetus on the content of cfDNA from the transplanted organ, accurately determines the concentration of cfDNA from the transplanted organ, has higher detection sensitivity, can be detected multiple times only by using peripheral blood of the patient, and achieves the purpose of long-term dynamic monitoring.

The invention relates to the technical field of neonatal fetal excrement collection and storage devices, in particular to a neonatal fetal excrement collection and storage device which is convenient to use and comprises disposable neonatal positioning pants, elastic adjusting belts are arranged at the left end and the right end of the disposable neonatal positioning pants, and a medical soft adhesive layer is arranged in the middle of the disposable neonatal positioning pants. An excrement storage round bag is arranged in the middle of the medical soft adhesive layer, an intelligent excrement and urine sensing patch is arranged on the rear portion of the excrement storage round bag, a connecting hard plastic opening is formed in the top end of the excrement storage round bag, a sampling sealing cover is arranged at the top end of the connecting hard plastic opening, and a fetal excrement storage sampling pipe is arranged at the rear end of the disposable newborn positioning trousers. A sampling suction port is formed in the bottom end of the fetus storing and sampling tube, a rubber ball cap is arranged at the top end of the fetus storing and sampling tube, an external thread groove is formed in the bottom of the fetus storing and sampling tube, a thread sealing cover is arranged at the bottom end of the fetus storing and sampling tube, and a sampling suction head plug block is arranged in the middle of the thread sealing cover.

1. The name of the design product: twin fetus information figure for electronic device interface. 2. The use of the design product: an electronic device. 3. The design points of the design product: the figure interface content in the screen, the element layout, the pattern and the interaction mode. 4. The picture or photo that best indicates the design points: the front view. 5. The use of the graphical user interface: the present graphical user interface is used for recording twin fetus and pregnant woman information. 6. The human-computer interaction mode of the graphical user interface: clicking "go to record" in the front view interface to enter the change state figure 1. Clicking the "other" icon in the upper right corner of the change state figure 1 to enter the change state figure 2; clicking the "basic information" in the upper right corner of the change state figure 2 to enter the change state figure 3.

An sgRNA targeting a porcine PLIN1 gene and use thereof. The sgRNA action site is located on the second exon and the fourth exon of the porcine PLIN1 gene. Provided is a method for knocking out a PLIN1 gene in a porcine fetal fibroblast cell line by using a CRISPR / CAS9 system. The method comprises designing and synthesizing an sgRNA targeting a porcine PLIN1 gene according to a porcine PLIN1 gene sequence, then constructing a CRISPR / Cas9 targeting vector containing the sgRNA, and transferring same into a porcine fetal fibroblast cell to obtain a PLIN1 gene-knocked-out porcine fetal fibroblast cell. The cell can be used for the preparation of a PLIN1 gene-edited porcine, and is not only of great significance for porcine breeding, but also of great reference value for revealing the occurrence mechanism of human hereditary lipodystrophy and seeking a treatment method.

The invention relates to the field of medical instruments, in particular to a movable emergency midwifery device for the obstetrical department. The parturition assisting device can assist a pregnant woman in more stable parturition, meanwhile, pain of the pregnant woman during parturition can be reduced, parturition of the pregnant woman is effectively assisted, and the pregnant woman feels more comfortable. A movable emergency midwifery device for the obstetrical department comprises a bed frame, moving wheels, supporting legs and the like. Four moving wheels are rotatably connected to the lower part of the bed frame, and two supporting legs are arranged at the top of the bed frame. The electric sliding block moves to drive the medical electric suction cup to move towards the side close to the sliding clamping rod and pull out the newborn, the electric sliding block moves reversely and does not drive the medical electric suction cup to move reversely, and the operation is repeated, so that the newborn is pulled out slowly and intermittently, and damage to a pregnant woman and the fetus due to continuous pulling of the fetus is avoided. Meanwhile, the working intensity and workload of workers can be relieved, and the midwifery efficiency is improved.